Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1 trials revealed osivelotor improved Hb concentration in sickle cell disease patients, suggesting its potential as an effective treatment.

Osivelotor treatment demonstrated improvements in Hb concentration and RBC deformability, suggesting meaningful pharmacodynamic activity.
The terminal elimination half-life of osivelotor in sickle cell disease participants was notably shorter at approximately 10 days.
Safety data indicated osivelotor was well tolerated across healthy participants and those with sickle cell disease without treatment discontinuation.
Dose-dependent pharmacokinetics supported the development of loading and maintenance dosing regimens for optimal therapeutic effects.

Lisbon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1 trials revealed osivelotor improved Hb concentration in sickle cell disease patients, suggesting its potential as an effective treatment.